Overall cervical dystonia improvement as · adults with cervical dystonia
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Participants with adverse events № of participants: 111 (1 RCT) · adults with cervical dystonia
Botulinum toxin type A showed no clear difference in participants with adverse events № of participants: 111 (1 RCT) compared with botulinum toxin type B (low certainty).
1 finding from 1 review
RR 1.4 [1, 1.96]
Studies not reported
Low
Subjective change as assessed by the patient at week 4 · adults with cervical dystonia
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Cervical dystonia‐specific pain · adults with cervical dystonia
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Adverse events: sore throat/dry mouth № of participants: 212 (2 RCTs) · adults with cervical dystonia
Botulinum toxin type A probably leads to higher adverse events: sore throat/dry mouth № of participants: 212 (2 RCTs) compared with botulinum toxin type B (moderate certainty).
1 finding from 1 review
RR 4.39 [2.43, 7.91]
Studies not reported
Moderate
Adverse events: dysphagia № of participants: 249 (3 RCTs) · adults with cervical dystonia
Botulinum toxin type A showed no clear difference in adverse events: dysphagia № of participants: 249 (3 RCTs) compared with botulinum toxin type B (low certainty).
1 finding from 1 review
RR 2.89 [0.8, 10.41]
Studies not reported
Low
Cervical dystonia‐specific improvement · cervical dystonia
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Adverse events · cervical dystonia
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Subjective Evaluation of Clinical Status · cervical dystonia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cervical dystonia‐specific pain · cervical dystonia
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Health‐related quality of life · cervical dystonia
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Withdrawals due to adverse events · cervical dystonia
It is very uncertain whether botulinum toxin type A changes tolerability assessed by dropouts due to adverse events compared with anticholinergics (very low certainty).
1 finding from 1 review
RR 0.33 [0.04, 3.04]
Studies not reported
Very low
Duration of effect · cervical dystonia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cervical dystonia‐specific improvement · cervical dystonia
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Adverse events at 4 weeks; 1085 participants (8 RCTs) · cervical dystonia
Botulinum toxin type A probably leads to higher adverse events at 4 weeks; 1085 participants (8 RCTs) compared with placebo (moderate certainty).
1 finding from 1 review
RR 1.23 [1.05, 1.43]
Studies not reported
Moderate
Subjective participant assessment at 4 weeks; 755 participants(6 RCTs) · cervical dystonia
Botulinum toxin type A leads to higher subjective participant assessment at 4 weeks; 755 participants(6 RCTs) compared with placebo (high certainty).
1 finding from 1 review
RR 2.19 [1.78, 2.7]
Studies not reported
High
Cervical dystonia‐specific pain · cervical dystonia
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Tolerability assessed as dropouts at 4 to 6 weeks: 705 participants (5 RCTs) · cervical dystonia
Botulinum toxin type A leads to lower tolerability assessed as dropouts at 4 to 6 weeks: 705 participants… compared with placebo (high certainty).
1 finding from 1 review
RR 0.48 [0.32, 0.73]
Studies not reported
High
Health‐related quality of life · cervical dystonia
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Duration of effect 618 participants (5 RCTs) · cervical dystonia
It is very uncertain whether botulinum toxin type A changes duration of effect 618 participants (5 RCTs) compared with placebo (very low certainty).
1 finding from 1 review
no estimate extracted
Studies not reported
Very low